Bill Gross warns on gold momentum as regional bank stocks tumble
Director William D. Waddill of Protagonist Therapeutics NASDAQ:PTGX, recently sold 12,000 shares of common stock for a total of $979480. The sales occurred on October 10, 2025, amid the company’s impressive 76% surge over the past six months. According to InvestingPro data, the company maintains a GREAT financial health score, with analysts maintaining a bullish outlook on the stock.
The shares were sold in two transactions. In the first transaction, 4,000 shares were sold at $69.25 per share. In the second transaction, 8,000 shares were sold at prices ranging from $86.71 to $88.00. With a current market capitalization of $4.8 billion, Protagonist Therapeutics has shown strong momentum, gaining over 20% in the past week alone. Track insider transactions and access 19 additional ProTips with InvestingPro.
On the same day, Waddill also exercised options to purchase 12,000 shares of Protagonist Therapeutics stock at an exercise price of $6.98, for a total value of $83760. The stock currently trades near its 52-week high of $93.25, reflecting the market’s positive sentiment toward the company’s prospects.
In other recent news, Protagonist Therapeutics has seen several notable developments. The company presented full data from the ANTHEM-UC trial for icotrokinra at Berlin’s UEG Conference, which reinforced investor confidence in the ulcerative colitis treatment. Following this, Clear Street raised its price target for Protagonist Therapeutics to $74, maintaining a Buy rating, after the trial results showed promising placebo-adjusted clinical response rates for all tested doses. BMO Capital also reiterated an Outperform rating with a price target of $72, emphasizing the trial’s positive impact. Additionally, Barclays initiated coverage with an Overweight rating and a $72 price target, highlighting the company’s peptide technology platform. JMP Securities increased its price target to $69, citing strong confidence in the upcoming new drug application for rusfertide in polycythemia vera. They noted a 90% probability of the drug’s approval next year. These developments reflect a period of active evaluation and optimism among analysts regarding Protagonist Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.